Meanwhile, recent updates hint at more issues in the group’s pipeline of bispecific MAbs.

After several disappointments Bristol at last turns its Lag3/PD-1 combo to first-line lung cancer.

Claudin18.2 is out, but the US big pharma opts in to a new project.

The company sticks with EZH2, despite others adding EZH1 inhibition.

Questions continue to swirl as the unit mulls another oncology makeover.